⚖
Compare Funds
See how two funds stack up side by side, real returns, risk, cost and portfolio overlap.
VS
Key Metrics Comparison
| Metric | ING Domestic Opportunities Fund - Growth | HDFC Pharma and Healthcare Fund - Growth - Direct Plan |
|---|---|---|
| Snapshot | ||
| AMC | ING MF | HDFC MF |
| Category | Equity - Multi Cap Fund | Equity - Sectoral Fund - Pharma & Health Care |
| NAV | ₹30.00 (23 Dec 2011) | ₹21.95 (30 Oct 2026) |
| Rating | ★★★ | ★★★★★ |
| Benchmark | BSE 200 | BSE Health Care - TRI |
| Fund Manager | Jasmina Parekh | Nikhil Mathur |
| Inception | 12 Sep 2004 | 04 Oct 2023 |
| Returns | ||
| 1Y | — | 22.64% |
| 3Y | — | 30.41% |
| 5Y | — | — |
| Since Inception | — | 29.15% |
| Risk | ||
| — | 14.07 | |
| — | 0.59 | |
| — | 1.59 | |
| — | 21.67 | |
| — | 3.48 | |
| — | -9.23% | |
| Costs | ||
| Expense Ratio | 2.50% | 1.03% |
| Exit Load | 1% on or before 365D,Nil after 365D | 1% on or before 30D, Nil after 30D |
| Min SIP | ₹1,000 | ₹100 |
| Min Lumpsum | ₹5,000 | ₹100 |
| Lock-in | None | None |
Min SIP is reported per fund, not per plan, every plan of a fund shares the same figure.
Portfolio Overlap
ING MF100%
HDFC MF100%
0.0%Only 0.0% of holdings by weight are common between ING MF and HDFC MF, based on each fund's top 20 disclosed holdings, not the full portfolio.
Category context: Equity vs Equity. Open the full Screener →